DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP)

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Kaushansky, Nathali ^a   Altmann, Daniel M ^b   David, Chella S ^c   Lassmann, Hans ^d   Ben Nun, Avraham ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c MAYO CLINIC   (United States)

^d Medical University of Vienna   (Austria)

Author keywords

Antigens peptides epitopes; EAE MS; HLA Tg mice; MHC; Neuroimmunology; T Cells

Indexed keywords

EPITOPE; GAMMA INTERFERON; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; PROTEOLIPID PROTEIN; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; HLA DQ ANTIGEN; HLA DRB1*15:01 ANTIGEN; HLA-DQB1 ANTIGEN; HLA-DRB1*15:01 ANTIGEN; PEPTIDE;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE PREDISPOSITION; ENZYME ACTIVITY; EX VIVO STUDY; IMMUNOGENICITY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TRANSGENICS; ALLERGIC ENCEPHALOMYELITIS; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPITOPES, T-LYMPHOCYTE; GENE EXPRESSION REGULATION; HLA-DQ BETA-CHAINS; HLA-DRB1 CHAINS; HUMANS; MICE; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; MYELIN PROTEOLIPID PROTEIN; PEPTIDES; T-LYMPHOCYTES;

EID: 84856617592     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-29     Document Type: Article

References (56)

1. de Rosbo NK, Ben-Nun A. T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein. J Autoimmun 1998, 11:287-299. 10.1006/jaut.1998.0202, 9776706.
2. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23:683-747. 10.1146/annurev.immunol.23.021704.115707, 15771584.
3. Kela-Madar N, de Rosbo NK, Ronen A, Mor F, Ben-Nun A. Autoimmune spread to myelin is associated with experimental autoimmune encephalomyelitis induced by a neuronal protein, beta-synuclein. J Neuroimmunol 2009, 208:19-29. 10.1016/j.jneuroim.2008.12.009, 19189872.
4. Huizinga R, Heijmans N, Schubert P, Gschmeissner S, t Hart BA, Herrmann H, Amor S. Immunization with neurofilament light protein induces spastic paresis and axonal degeneration in Biozzi ABH mice. J Neuropathol Exp Neurol 2007, 66:295-304. 10.1097/nen.0b013e318040ad5c, 17413320.
5. Giovannoni G, Ebers G. Multiple sclerosis: the environment and causation. Curr Opin Neurol 2007, 20:261-268. 10.1097/WCO.0b013e32815610c2, 17495618.
6. Ramagopalan SV, Dyment DA, Ebers GC. Genetic epidemiology: the use of old and new tools for multiple sclerosis. Trends Neurosci 2008, 31:645-652. 10.1016/j.tins.2008.09.001, 18952304.
7. Sawcer S. The complex genetics of multiple sclerosis: pitfalls and prospects. Brain 2008, 131:3118-3131. 10.1093/brain/awn081, 2639203, 18490360.
8. Oksenberg JR, Barcellos LF, Hauser SL. Genetic aspects of multiple sclerosis. Semin Neurol 1999, 19:281-288. 10.1055/s-2008-1040844, 12194384.
9. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008, 9:516-526. 10.1038/nrg2395, 18542080.
10. McElroy JP, Oksenberg JR. Multiple sclerosis genetics. Neurol Clin 2010, 29:219-231.
11. Miretti MM, Walsh EC, Ke X, Delgado M, Griffiths M, Hunt S, Morrison J, Whittaker P, Lander ES, Cardon LR, et al. A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms. Am J Hum Genet 2005, 76:634-646. 10.1086/429393, 1199300, 15747258.
12. Ramagopalan SV, Ebers GC. Multiple sclerosis: major histocompatibility complexity and antigen presentation. Genome Med 2009, 1:105. 10.1186/gm105, 2808740, 19895714.
13. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006, 52:61-76. 10.1016/j.neuron.2006.09.011, 17015227.
14. Oksenberg JR, Baranzini SE. Multiple sclerosis genetics--is the glass half full, or half empty?. Nat Rev Neurol 2010, 6:429-437. 10.1038/nrneurol.2010.91, 20625377.
15. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219. 10.1038/nature10251, 3182531, 21833088.
16. Serjeantson SW, Gao X, Hawkins BR, Higgins DA, Yu YL. Novel HLA-DR2-related haplotypes in Hong Kong Chinese implicate the DQB1*0602 allele in susceptibility to multiple sclerosis. Eur J Immunogenet 1992, 19:11-19. 10.1111/j.1744-313X.1992.tb00043.x, 1567812.
17. Spurkland A, Celius EG, Knutsen I, Beiske A, Thorsby E, Vartdal F. The HLA-DQ(alpha 1*0102, beta 1*0602) heterodimer may confer susceptibility to multiple sclerosis in the absence of the HLA-DR(alpha 1*01, beta 1*1501) heterodimer. Tissue Antigens 1997, 50:15-22. 10.1111/j.1399-0039.1997.tb02828.x, 9243750.
18. Oksenberg JR, Barcellos LF, Cree BA, Baranzini SE, Bugawan TL, Khan O, Lincoln RR, Swerdlin A, Mignot E, Lin L, et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 2004, 74:160-167. 10.1086/380997, 1181903, 14669136.
19. Wucherpfennig KW, Zhang J, Witek C, Matsui M, Modabber Y, Ota K, Hafler DA. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol 1994, 152:5581-5592.
20. Martin R, Jaraquemada D, Flerlage M, Richert J, Whitaker J, Long EO, McFarlin DE, McFarland HF. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol 1990, 145:540-548.
21. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990, 346:183-187. 10.1038/346183a0, 1694970.
22. Valli A, Sette A, Kappos L, Oseroff C, Sidney J, Miescher G, Hochberger M, Albert ED, Adorini L. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest 1993, 91:616-628. 10.1172/JCI116242, 287995, 7679413.
23. Douek DC, Altmann DM. T-cell apoptosis and differential human leucocyte antigen class II expression in human thymus. Immunology 2000, 99:249-256. 10.1046/j.1365-2567.2000.00940.x, 2327152, 10692044.
24. Altmann DM, Douek DC, Frater AJ, Hetherington CM, Inoko H, Elliott JI. The T cell response of HLA-DR transgenic mice to human myelin basic protein and other antigens in the presence and absence of human CD4. J Exp Med 1995, 181:867-875. 10.1084/jem.181.3.867, 2191922, 7532684.
25. Mangalam AK, Khare M, Krco C, Rodriguez M, David C. Identification of T cell epitopes on human proteolipid protein and induction of experimental autoimmune encephalomyelitis in HLA class II-transgenic mice. Eur J Immunol 2004, 34:280-290. 10.1002/eji.200324597, 14971054.
26. Kawamura K, Yamamura T, Yokoyama K, Chui DH, Fukui Y, Sasazuki T, Inoko H, David CS, Tabira T. Hla-DR2-restricted responses to proteolipid protein 95-116 peptide cause autoimmune encephalitis in transgenic mice. J Clin Invest 2000, 105:977-984. 10.1172/JCI8407, 377477, 10841661.
27. Rich C, Link JM, Zamora A, Jacobsen H, Meza-Romero R, Offner H, Jones R, Burrows GG, Fugger L, Vandenbark AA. Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. Eur J Immunol 2004, 34:1251-1261. 10.1002/eji.200324354, 15114658.
28. Kaushansky N, Altmann DM, Ascough S, David CS, Lassmann H, Ben-Nun A. HLA-DQB1*0602 determines disease susceptibility in a new "humanized" multiple sclerosis model in HLA-DR15 (DRB1*1501;DQB1*0602) transgenic mice. J Immunol 2009, 183:3531-3541. 10.4049/jimmunol.0900784, 19648275.
29. Khare M, Mangalam A, Rodriguez M, David CS. HLA DR and DQ interaction in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in HLA class II transgenic mice. J Neuroimmunol 2005, 169:1-12. 10.1016/j.jneuroim.2005.07.023, 16194572.
30. Mangalam A, Luckey D, Basal E, Behrens M, Rodriguez M, David C. HLA-DQ6 (DQB1*0601)-restricted T cells protect against experimental autoimmune encephalomyelitis in HLA-DR3.DQ6 double-transgenic mice by generating anti-inflammatory IFN-gamma. J Immunol 2008, 180:7747-7756. 2576747, 18490779.
31. Marrosu MG, Muntoni F, Murru MR, Costa G, Pischedda MP, Pirastu M, Sotgiu S, Rosati G, Cianchetti C. HLA-DQB1 genotype in Sardinian multiple sclerosis: evidence for a key role of DQB1 *0201 and *0302 alleles. Neurology 1992, 42:883-886.
32. Greer JM, Csurhes PA, Muller DM, Pender MP. Correlation of blood T cell and antibody reactivity to myelin proteins with HLA type and lesion localization in multiple sclerosis. J Immunol 2008, 180:6402-6410.
33. Lock CB, So AK, Welsh KI, Parkes JD, Trowsdale J. MHC class II sequences of an HLA-DR2 narcoleptic. Immunogenetics 1988, 27:449-455. 10.1007/BF00364432, 3259543.
34. Cosgrove D, Gray D, Dierich A, Kaufman J, Lemeur M, Benoist C, Mathis D. Mice lacking MHC class II molecules. Cell 1991, 66:1051-1066. 10.1016/0092-8674(91)90448-8, 1909605.
35. Zhong MC, Kerlero de Rosbo N, Ben-Nun A. Multiantigen/multiepitope-directed immune-specific suppression of "complex autoimmune encephalomyelitis" by a novel protein product of a synthetic gene. J Clin Invest 2002, 110:81-90. 151033, 12093891.
36. de Rosbo NK, Kaye JF, Eisenstein M, Mendel I, Hoeftberger R, Lassmann H, Milo R, Ben-Nun A. The myelin-associated oligodendrocytic basic protein region MOBP15-36 encompasses the immunodominant major encephalitogenic epitope(s) for SJL/J mice and predicted epitope(s) for multiple sclerosis-associated HLA-DRB1*1501. J Immunol 2004, 173:1426-1435.
37. Zhong MC, Cohen L, Meshorer A, Kerlero de Rosbo N, Ben-Nun A. T-cells specific for soluble recombinant oligodendrocyte-specific protein induce severe clinical experimental autoimmune encephalomyelitis in H-2(b) and H-2(s) mice. J Neuroimmunol 2000, 105:39-45. 10.1016/S0165-5728(00)00186-7, 10713362.
38. Ben-Nun A, Rosbo N, Kaushansky N, Eisenstein M, Cohen L, Kaye JF, Mendel I. Anatomy of T cell autoimmunity to myelin oligodendrocyte glycoprotein (MOG): prime role of MOG44F in selection and control of MOG-reactive T cells in H-2b mice. Eur J Immunol 2006, 36:478-493. 10.1002/eji.200535363, 16453383.
39. Kaushansky N, Zilkha-Falb R, Hemo R, Lassman H, Eisenstein M, Sas A, Ben-Nun A. Pathogenic T cells in MOBP-induced murine EAE are predominantly focused to recognition of MOBP21F and MOBP27P epitopic residues. Eur J Immunol 2007, 37:3281-3292. 10.1002/eji.200737438, 17935073.
40. Marsh SG, Bodmer JG. HLA class II nucleotide sequences, 1992. Hum Immunol 1992, 35:1-17. 10.1016/0198-8859(92)90090-A, 1478891.
41. Ong B, Willcox N, Wordsworth P, Beeson D, Vincent A, Altmann D, Lanchbury JS, Harcourt GC, Bell JI, Newsom-Davis J. Critical role for the Val/Gly86 HLA-DR beta dimorphism in autoantigen presentation to human T cells. Proc Natl Acad Sci USA 1991, 88:7343-7347. 10.1073/pnas.88.16.7343, 52291, 1714600.
42. Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 2008, 14:337-342. 10.1038/nm1715, 2813727, 18278054.
43. Tuohy VK. Peptide determinants of myelin proteolipid protein (PLP) in autoimmune demyelinating disease: a review. Neurochem Res 1994, 19:935-944. 10.1007/BF00968703, 7528355.
44. Alves-Leon SV, Papais-Alvarenga R, Magalhaes M, Alvarenga M, Thuler LC, Fernandez y Fernandez O. Ethnicity-dependent association of HLA DRB1-DQA1-DQB1 alleles in Brazilian multiple sclerosis patients. Acta Neurol Scand 2007, 115:306-311. 10.1111/j.1600-0404.2006.00750.x, 17489940.
45. Lincoln MR, Ramagopalan SV, Chao MJ, Herrera BM, Deluca GC, Orton SM, Dyment DA, Sadovnick AD, Ebers GC. Epistasis among HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility. Proc Natl Acad Sci USA 2009, 106:7542-7547. 2678609, 19380721.
46. Amirzargar A, Mytilineos J, Yousefipour A, Farjadian S, Scherer S, Opelz G, Ghaderi A. HLA class II (DRB1, DQA1 and DQB1) associated genetic susceptibility in Iranian multiple sclerosis (MS) patients. Eur J Immunogenet 1998, 25:297-301. 10.1046/j.1365-2370.1998.00101.x, 9777330.
47. Waldner H, Whitters MJ, Sobel RA, Collins M, Kuchroo VK. Fulminant spontaneous autoimmunity of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell receptor. Proc Natl Acad Sci USA 2000, 97:3412-3417. 10.1073/pnas.97.7.3412, 16253, 10737797.
48. Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 1993, 72:551-560. 10.1016/0092-8674(93)90074-Z, 7679952.
49. Whitham RH, Bourdette DN, Hashim GA, Herndon RM, Ilg RC, Vandenbark AA, Offner H. Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis. J Immunol 1991, 146:101-107.
50. Bielekova B, Sung MH, Kadom N, Simon R, McFarland H, Martin R. Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol 2004, 172:3893-3904.
51. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000, 6:1167-1175. 10.1038/80516, 11017150.
52. Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P, Mychaleckyj JC, Todd JA, Bonella P, Fear AL, et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 2008, 57:1084-1092. 10.2337/db07-1331, 18252895.
53. Tjon JM, van Bergen J, Koning F. Celiac disease: how complicated can it get?. Immunogenetics 2010, 62:641-651. 10.1007/s00251-010-0465-9, 2944025, 20661732.
54. Vandenbark AA, Chou YK, Whitham R, Mass M, Buenafe A, Liefeld D, Kavanagh D, Cooper S, Hashim GA, Offner H. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat Med 1996, 2:1109-1115. 10.1038/nm1096-1109, 8837609.
55. Steinman L. Antigen-specific therapy of multiple sclerosis: the long-sought magic bullet. Neurotherapeutics 2007, 4:661-665. 10.1016/j.nurt.2007.07.007, 17920547.
56. Muraro PA, Wandinger KP, Bielekova B, Gran B, Marques A, Utz U, McFarland HF, Jacobson S, Martin R. Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain 2003, 126:20-31.